| Date | Title | Description |
| 15.10.2024 | PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration | Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort.
PMC-403 is being explored in broader therapeutic areas, including rare vascular disease ... |
| 08.07.2024 | PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors | PMC-309 receives safety approval for first dose cohort (0.2mg/kg), and second dose cohort (0.5mg/kg) is currently underway in Australia.
DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stag... |
| 02.07.2024 | PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg | Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of PMC-403
DAEJEON, South Korea, July 2, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 20834... |
| 01.07.2024 | PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg | Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of PMC-403
DAEJEON, South Korea, July 2, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 20834... |
| 27.05.2024 | Revolutionizing Eye Treatment: The Future of Non-Invasive Therapy | The recent presentation at ARVO 2024 by PharmAbcine's U.S. subsidiary, Wincal Biopharm, has sparked excitement in the medical community. Their innovative eye drop formulations have shown promising results in animal studies, potentially chan... |
| 23.05.2024 | PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024 | Presentation at ARVO 2024 gained attention as Eylea (aflibercept) eye drops demonstrated similar efficacy to intravitreal injections in animal studies.
DAEJEON, South Korea, May 23, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine&... |
| 22.05.2024 | PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024 | Presentation at ARVO 2024 gained attention as Eylea (aflibercept) eye drops demonstrated similar efficacy to intravitreal injections in animal studies.
DAEJEON, South Korea , May 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine... |
| 24.01.2024 | PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors | Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309 monotherapy and combination therapy with KEYTRUDA®
The clinical trial aims to enroll a total of 67 patients across four institutions in Australi... |
| 23.11.2023 | PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome | Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a. Clarkson Disease) and vessel-related rare disease indications
Unique Tie2-activating antibody program, PMC-403, demonstrates efficacy... |
| 09.11.2023 | PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data | Safety Review Committee evaluated dose level 1 safety data of PMC-403 and approved advancing to the higher dose treatment.
The starting dose (0.7mg) of PMC-403 showed potential in improving eyesight for neovascular age-related macular degen... |
| 26.07.2023 | PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD | DAEJEON, South Korea, July 26, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the first patient has been ... |
| 23.05.2023 | PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD | DAEJEON, South Korea, May 23, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company received IND (In... |
| 08.05.2023 | PharmAbcine to participate in "BIO International Convention 2023" | DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in t... |
| 12.12.2022 | PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab) | DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered int... |
| 08.12.2022 | PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week | DAEJEON, South Korea, Dec. 8, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited to pa... |
| 17.10.2022 | PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 | DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data o... |
| 26.09.2022 | PharmAbcine to Participate in BIO-Europe 2022 | DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participa... |
| 11.05.2022 | PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention | DAEJEON, South Korea, May 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that Dr. Jin-San Yoo, Chairman an... |
| 26.04.2022 | PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study | DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the positive results from the G... |
| 26.04.2022 | PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology | DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the appointment of Quan Dong Ng... |
| 11.04.2022 | PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022 | DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an u... |
| 21.03.2022 | RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics | SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, announced today that it has signed a Collaborative Researc... |
| 14.03.2022 | NuclixBio Announces a Collaborative Research Agreement with PharmAbcine | SEOUL, South Korea, March 14, 2022 /PRNewswire/ -- NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with Phar... |
| 25.02.2022 | PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial | DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient l... |
| 19.10.2021 | PharmAbcine Announces Patent Grant in Australia for Its Anti-VISTA Antibody | DAEJEON, South Korea, Oct. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the patent for PMC-309, one... |
| 20.09.2021 | PharmAbcine to Participate in BIO-Europe 2021 | DAEJEON, South Korea, Sept. 20, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually... |
| 13.09.2021 | PharmAbcine to Participate in ACCESS CHINA Biotech Forum | DAEJEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually... |
| 09.09.2021 | PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer | DAEJEON, South Korea, Sept. 9, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperatio... |
| 09.09.2021 | PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer | |
| 03.09.2021 | PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC | |
| 03.09.2021 | PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC | DAEJEON, South Korea, Sept. 3, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Eth... |
| 23.08.2021 | PharmAbcine to Participate in H.C. Wainright 23rd Annual Global Investment Conference | DAEJEON, South Korea, Aug. 23, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participat... |
| 19.08.2021 | PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases | |
| 19.08.2021 | PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases | DAEJEON, South Korea, Aug. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperatio... |
| 17.08.2021 | PharmAbcine to Participate in Biotechgate Digital Partnering | DAEJEON, South Korea, Aug. 17, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participat... |
| 26.07.2021 | PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference | DAEJEON, South Korea, July 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the company is invited to d... |
| 02.06.2021 | PharmAbcine to Present at the BIO Digital International Convention 2021 | DAEJEON, South Korea, June 2, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will participate in BIO Digital ... |
| 10.05.2021 | PharmAbcine Announces Encouraging Non-clinical Data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting | DAEJEON, South Korea, May 10, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring ... |
| 19.04.2021 | PharmAbcine announces Clinical Trial Collaboration with MSD for the Phase II study in mTNBC | |
| 11.01.2021 | PharmAbcine announces a research collaboration with LegoChem Biosciences | |
| 21.09.2020 | PharmAbcine expands partnership with Samsung Biologics for PMC-403 | |
| 16.09.2009 | Korean PharmAbcine Closes US $6M Series A Financing | PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, received US $6m in a Series A financing.
The round was co-led by OrbiMed’s Cad... |
